Subgroup Analyses

Cross-source consensus on Subgroup Analyses from 1 sources and 5 claims.

1 sources · 5 claims

Comparisons

The subgroup findings were exploratory and hypothesis-generating rather than evidence of efficacy. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
No statistically significant treatment-by-subgroup interactions were observed in the mITT population. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
Exploratory subgroup analyses examined whether LVESVI treatment effects varied by baseline disease severity and clinical characteristics. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
Patients with baseline LVESVI above the median and NT-proBNP above the median showed numerical trends favoring CDR132L. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
Subgroup effects were generally larger in the per-protocol population than in the modified intention-to-treat population. — The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial